HCV / Hepatitis

Small studies show good outcomes for previously uninfected recipients who receive kidneys from donors infected with hepatitis.

The combination of direct-acting antiviral agents glecaprevir/pibrentasvir (G/P), sofosbuvir, and ribavirin is now approved for new patient populations.

Millions with viral hepatitis go undiagnosed and untreated.

Suicide is a major problem for many patients with infectious diseases but pinpointing the exact cause has proven difficult.

An increase in injection drug use in the United States has augmented the likelihood of acquiring HCV, particularly genotype 3.

The new guidelines include updates on HCV management and testing in pregnant women, individuals who inject drugs, men who have sex with men, and individuals who are incarcerated.

Infections associated with the ongoing opioid epidemic in the United States apparently know no bounds.

Unique considerations are called for when caring for intravenous drug users with newly diagnosed HIV/HCV coinfections.

The risk comes after it was found that surgical instruments used for orthopedic and spine surgeries were not cleaned properly and consequently, the sterilization of those instruments was compromised.

Falsified hepatitis B vaccines were discovered at 8 health facilities in Uganda.

Treatment-experienced patients still have some good options.

Herewith, 4 New Year’s resolutions for the infectious disease community—at least according to us here on the Public Health Watch.

The results of a new study show that when a best practice advisory (BPA) displayed in the electronic health record of patients in the baby boomer generation, it prompted a 5-fold increase in screening for hepatitis C virus (HCV) in this population.

Hepatitis C is more curable than ever thanks to direct-acting antivirals, and now, a new study shows how expanded access to these drugs through Medicaid is helping more individuals get treated.

The results of a new study show that patients who are co-infected with the hepatitis C virus (HCV) and HIV can experience cure rates similar to individuals infected with HCV alone when both groups receive direct-acting antiviral drugs.

The vaccine is the only 2-dose regimen for the prevention of infection by all known subtypes of hepatitis b in adults 18 and older.

Despite the availability of highly active agents against HCV, HIV-infected patients require special considerations for drug interactions when considering treatment options.

The ambitious goal of global elimination of the virus by 2030 will take buy-in from all major stakeholders, including the United States.

Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.

The results of a 5-year study show that coffee drinking can cut down the risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) infections.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

A new study reveals that direct-acting antivirals, like sofosbuvir, may help improve kidney function in some patients.

Phase 3 study shows that combination of elbasvir and grazoprevir is highly efficacious in hepatitis C virus (HCV) infected patients with inherited blood disorders.

Routine, rapid hepatitis C virus (HCV) testing may be a cost-effective method to help decrease the prevalence of new infections in high-risk communities.

The results of a new study have shown that an integrated care (IC) program can be successful in providing treatment to patients infected with hepatitis C virus (HCV) who were unlikely to respond to traditional outreach efforts.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Researchers from the Department of Dermatology at the Northwestern University Feinberg School of Medicine have found no correlation between having psoriasis and the prevalence of hepatitis B or C.

The New York State Department of Health warns of potential disease exposure in two facility locations in Westchester County.

Janssen announces a strategic decision to discontinue the development of investigational hepatitis C treatment, JNJ-4178, a triple-combination drug, consisting of three direct-acting antivirals.